Amicus Therapeutics Share Price Nasdaq
Equities
Biotechnology & Medical Research
Sales 2024 * | 510M 40.34B | Sales 2025 * | 642M 50.73B | Capitalization | 2.94B 232B |
---|---|---|---|---|---|
Net income 2024 * | -72M -5.69B | Net income 2025 * | 65M 5.14B | EV / Sales 2024 * | 6.11 x |
Net Debt 2024 * | 182M 14.37B | Net Debt 2025 * | 84.17M 6.65B | EV / Sales 2025 * | 4.7 x |
P/E ratio 2024 * |
-41.7
x | P/E ratio 2025 * |
47.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.78% |
Latest transcript on Amicus Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 31/03/06 |
Simon Harford
DFI | Director of Finance/CFO | 63 | 20/08/23 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 30/06/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 31/03/06 |
Lynn Bleil
BRD | Director/Board Member | 60 | 10/09/18 |
Burke Whitman
BRD | Director/Board Member | 68 | 26/06/19 |
1st Jan change | Capi. | |
---|---|---|
+21.85% | 46.44B | |
+38.76% | 39.1B | |
-8.05% | 38.76B | |
+29.04% | 31.24B | |
-13.75% | 25.8B | |
+10.65% | 25.9B | |
+38.43% | 13.12B | |
-6.92% | 11.32B | |
-12.29% | 10.68B |